Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection

Key Inclusion Criteria: * Must have participated in a Gilead-sponsored chronic hepatitis B (CHB) study no more than 120 days prior to Baseline (Day 1), except for participants from previous Gilead-sponsored study number GS-US-174-0149, who will have up to one year from their last visit in that protocol. * Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures * Must be willing and able to comply with the visit schedule and study requirements * Must have documented HBV DNA \< 2,000 IU/mL at time of screening visit, which shall occur no later than 1 year post last study visit in GS-US-174-0149 * Must have documented hepatitis B surface antigen (HBsAg) negative status anytime during participation in GS-US-174-0149 regardless of ongoing HBV treatment Key Exclusion Criteria: * Patient participating or planning to participate in another clinical study with an investigational agent * History of clinically-significant illness or any other major medical disorder that may interfere with follow-up, assessments or compliance with the protocol * Believed by the Study Investigator to be inappropriate for study participation for any reason not otherwise listed * Received TDF monotherapy either as part of GS-US-174-0149 Arm C (TDF monotherapy arm) or for TDF retreatment, and have taken any HBV antiviral therapy since completion of GS-US-174-0149 Note: Other protocol defined Inclusion/Exclusion criteria may apply.